TY - JOUR
T1 - A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
AU - Tannir, Nizar M.
AU - Plimack, Elizabeth
AU - Ng, Chaan
AU - Tamboli, Pheroze
AU - Bekele, Nebiyou B.
AU - Xiao, Lianchun
AU - Smith, Lisa
AU - Lim, Zita
AU - Pagliaro, Lance C
AU - Araujo, John
AU - Aparicio, Ana
AU - Matin, Surena
AU - Wood, Christopher G
AU - Jonasch, Eric
N1 - Funding Information:
Financial disclosures : Nizar M. Tannir certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Nizar M. Tannir has received research funding from Pfizer, and served on the advisory boards of Pfizer. Elizabeth Plimack has served as a consultant to and on the advisory board of Pfizer. Eric Jonasch has served as a consultant to and has received funding from Pfizer. Christopher G Wood has served as a consultant to and advisory board of Pfizer.
Funding Information:
Funding/Support and role of the sponsor : This study was funded by Pfizer Pharmaceuticals (award number CS2006-00018400JW).
PY - 2012/12
Y1 - 2012/12
N2 - Background: Sunitinib is a standard-of-care treatment in advanced clear cell renal cell carcinoma (ccRCC). Retrospective and expanded access data suggest sunitinib has activity in advanced non-clear cell renal cell carcinoma (nccRCC). Objective: To prospectively determine the clinical efficacy and safety of sunitinib in patients with advanced nccRCC. Design, setting, and participants: This is a single-arm phase 2 trial with a two-stage design. Eligibility criteria included pathologically confirmed nccRCC or ccRCC with ≥20% sarcomatoid histology, performance status 0-2, measurable disease, a maximum of two prior systemic therapies, and no prior treatment with tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptors. Intervention: Patients received sunitinib 50 mg daily on a 4-wk on, 2-wk off schedule. Outcome measurements and statistical analysis: Primary end points were objective response rate (ORR) and progression-free survival (PFS). Secondary end points were safety and overall survival (OS). Results and limitations: Fifty-seven patients were eligible (nccRCC histology: papillary, 27; chromophobe, 5; unclassified, 8; collecting duct or medullary carcinoma, 6; sarcomatoid, 7; and others, 4). Median PFS for 55 evaluable patients was 2.7 mo (95% confidence interval [CI], 1.4-5.4). Two patients with chromophobe and one patient with unclassified histology had a confirmed partial response (5% ORR). Median PFS for patients with papillary histology was 1.6 mo (95% CI, 1.4-5.4). Median PFS for patients with chromophobe histology was 12.7 mo (95% CI, 8.5-NA). Median OS for all patients was 16.8 mo (95% CI, 10.7-26.3). Treatment-emergent adverse events were consistent with sunitinib's mechanism of action. The nonrandomized design and small number of patients are limitations of this study. Conclusions: The differential response of chromophobe histology to sunitinib suggests a therapeutically relevant biological heterogeneity exists within nccRCC. The low ORR and short PFS with sunitinib in the other nccRCC subtypes underscore the need to enroll patients with these diverse tumors in clinical trials.
AB - Background: Sunitinib is a standard-of-care treatment in advanced clear cell renal cell carcinoma (ccRCC). Retrospective and expanded access data suggest sunitinib has activity in advanced non-clear cell renal cell carcinoma (nccRCC). Objective: To prospectively determine the clinical efficacy and safety of sunitinib in patients with advanced nccRCC. Design, setting, and participants: This is a single-arm phase 2 trial with a two-stage design. Eligibility criteria included pathologically confirmed nccRCC or ccRCC with ≥20% sarcomatoid histology, performance status 0-2, measurable disease, a maximum of two prior systemic therapies, and no prior treatment with tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptors. Intervention: Patients received sunitinib 50 mg daily on a 4-wk on, 2-wk off schedule. Outcome measurements and statistical analysis: Primary end points were objective response rate (ORR) and progression-free survival (PFS). Secondary end points were safety and overall survival (OS). Results and limitations: Fifty-seven patients were eligible (nccRCC histology: papillary, 27; chromophobe, 5; unclassified, 8; collecting duct or medullary carcinoma, 6; sarcomatoid, 7; and others, 4). Median PFS for 55 evaluable patients was 2.7 mo (95% confidence interval [CI], 1.4-5.4). Two patients with chromophobe and one patient with unclassified histology had a confirmed partial response (5% ORR). Median PFS for patients with papillary histology was 1.6 mo (95% CI, 1.4-5.4). Median PFS for patients with chromophobe histology was 12.7 mo (95% CI, 8.5-NA). Median OS for all patients was 16.8 mo (95% CI, 10.7-26.3). Treatment-emergent adverse events were consistent with sunitinib's mechanism of action. The nonrandomized design and small number of patients are limitations of this study. Conclusions: The differential response of chromophobe histology to sunitinib suggests a therapeutically relevant biological heterogeneity exists within nccRCC. The low ORR and short PFS with sunitinib in the other nccRCC subtypes underscore the need to enroll patients with these diverse tumors in clinical trials.
KW - Chromophobe renal cell carcinoma
KW - Non-clear cell renal cell carcinoma
KW - Papillary renal cell carcinoma
KW - Renal cell carcinoma variant histology
KW - Sunitinib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84868532639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868532639&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2012.06.043
DO - 10.1016/j.eururo.2012.06.043
M3 - Article
C2 - 22771265
AN - SCOPUS:84868532639
SN - 0302-2838
VL - 62
SP - 1013
EP - 1019
JO - European urology
JF - European urology
IS - 6
ER -